CANF Stock Overview
A clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Can-Fite BioPharma Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪1.79 |
| 52 Week High | ₪4.69 |
| 52 Week Low | ₪1.29 |
| Beta | 0.46 |
| 1 Month Change | -10.05% |
| 3 Month Change | -9.14% |
| 1 Year Change | -10.05% |
| 3 Year Change | -86.02% |
| 5 Year Change | -93.56% |
| Change since IPO | -99.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| CANF | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 17.4% | -1.9% | -2.8% |
| 1Y | -10.1% | -5.7% | 24.1% |
Return vs Industry: CANF underperformed the US Biotechs industry which returned -6.3% over the past year.
Return vs Market: CANF underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| CANF volatility | |
|---|---|
| CANF Average Weekly Movement | 11.8% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CANF's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CANF's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 8 | Motti Farbstein | www.canfite.com |
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction.
Can-Fite BioPharma Ltd. Fundamentals Summary
| CANF fundamental statistics | |
|---|---|
| Market cap | US$11.21m |
| Earnings (TTM) | -US$7.37m |
| Revenue (TTM) | US$667.00k |
16.8x
P/S Ratio-1.5x
P/E RatioIs CANF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CANF income statement (TTM) | |
|---|---|
| Revenue | US$667.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$667.00k |
| Other Expenses | US$8.04m |
| Earnings | -US$7.37m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0036 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,105.10% |
| Debt/Equity Ratio | 0% |
How did CANF perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 20:06 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Can-Fite BioPharma Ltd. is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | CG Capital |
| Jason Kolbert | D. Boral Capital LLC. |
| Deepak Sonawane | Haitong International Research Limited |